In 2020, the ADAURA study showed the overwhelming efficacy of osimertinib for adjuvant treatment of patients with stage IB–IIIA NSCLC harboring EGFR mutation [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.